{
    "clinical_study": {
        "@rank": "157889", 
        "acronym": "PROCOG-SEP", 
        "arm_group": [
            {
                "arm_group_label": "procog", 
                "arm_group_type": "Experimental", 
                "description": "cognitive remedial program 13 sessions over a 6-month period"
            }, 
            {
                "arm_group_label": "DISINT", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Interactive discussion program of 13 group sessions in a 6-month period"
            }
        ], 
        "brief_summary": {
            "textblock": "Cognitive disorders are well-known in multiple sclerosis (MS), even in earlier stages of the\n      disease. They effect personal life. Their management may be overlooked. The evidence-based\n      program proposes exercises to both stimulate preserved functions and develop new abilities\n      compensating for cognitive disabilities.\n\n      Aim of the study is to evaluate the efficiency of the remedial program (PROCOG-SEP) designed\n      for MS patients, compared to an interactive discussion program(DISINT) 140 multiple\n      sclerosis patients will be randomly assigned in one the program for 13 sessions over a\n      6-month period.\n\n      Main outcome criteria is evolution of SRT-LIST before and after program."
        }, 
        "brief_title": "Evaluation of the Efficiency of a Cognitive Remedial Program (PROCOG-SEP) Designed for Multiple Sclerosis Patients", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cognitive Disorders", 
            "Multiple Sclerosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cognition Disorders", 
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  18 \u2264Aged \u2264 50 at baseline\n\n          -  Must be able to understand and read french language\n\n          -  Must sign the informed consent form\n\n          -  Must be affiliate to French social security\n\n          -  multiple sclerosis confirmed by Mac Donald criteria\n\n          -  EDSS \u2264 5.0 at baseline\n\n          -  Duration of multiple sclerosis \u2264 20 years at baseline\n\n          -  mild cognitive disorder ( at least 2 cognitive tasks, at most 5 )\n\n        Exclusion Criteria:\n\n          -  under legal protection\n\n          -  treatment by corticosteroids in the past 4 weeks\n\n          -  cognitive remedial program already done\n\n          -  neuropsychologic assessment in the past 3 months\n\n          -  having an other chronic disease\n\n          -  having an other neurologic disease\n\n          -  alcohol or drug addiction"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01659593", 
            "org_study_id": "PROCOG-SEP"
        }, 
        "intervention": [
            {
                "arm_group_label": "procog", 
                "description": "3 to 5 people group program", 
                "intervention_name": "procog", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "DISINT", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "cognitive disorders", 
            "multiple sclerosis", 
            "neuropsychology"
        ], 
        "lastchanged_date": "August 30, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nancy", 
                    "country": "France", 
                    "zip": "54000"
                }, 
                "name": "University hospital Nancy"
            }, 
            "investigator": {
                "last_name": "Marc Debouverie, MD,PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluation of the Efficiency of a Cognitive Remedial Program (PROCOG-SEP) Designed for Multiple Sclerosis Patients. A Double Blind Randomized Multicenter Trial.", 
        "other_outcome": {
            "measure": "cognitive function: verbal memory (SRT), visuospatial memory (10/36), verbal fluency (animal categories),empans, code ,DO80, cognitive complaint", 
            "safety_issue": "No", 
            "time_frame": "0-9 months"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: National Consultative Ethics Committee for Health and Life Sciences", 
                "France: The Commission nationale de l\u2019informatique et des libert\u00e9s"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "cognitive function measured by SRT-List score", 
            "safety_issue": "No", 
            "time_frame": "0-9 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01659593"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "quality of life measured by MusiQol", 
            "safety_issue": "No", 
            "time_frame": "0 -9 months"
        }, 
        "source": "Central Hospital, Nancy, France", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University Hospital, Strasbourg, France", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Centre Hospitalier Universitaire Dijon", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Centre Hospitalier Universitaire de Besancon", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Central Hospital, Nancy, France", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}